Acorda Therapeutics — Q4 2022 Earnings Presentation
20 slides from Acorda Therapeutics's earnings presentation, Mar 9, 2023
Slide 1: Acorda Therapeutics 2022 Q4 YE Earnings Call
Acorda Therapeutics 2022 Q4 YE Earnings Call March 9, 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncerta
Slide 3: 2022 / Early 2023 Accomplishments
2022 / Early 2023 Accomplishments 2022 2023 INBRIJA Licensed Long term Paid December Re-negotiated INBRIJA commercialization preclinical financial interest payment INBRIJA commercial agreement with asset to guidance in cash, not manufacturing launch in Spain Biopas for Latin Asieris provided shares
Slide 4: Inbrija capsules
ng capsules
Slide 5: INBRIJA Net U.S. Sales – Q4 and YE 2022
INBRIJA Net U.S. Sales – Q4 and YE 2022 $28M $9M Q4 2022 2022 net sales net sales 13.1% < Q4 2021 5.6% < 2021 146% > Q1 2022 2022 Guidance $27.8M - $28.7M 5 2022 Q4/YE EARNINGS
Slide 6: INBRIJA U.S. Trends Since Launch
INBRIJA U.S. Trends Since Launch Net Sales $M 12.0 10.0 10.4 9.4 9.0 8.0 7.8 7.6 7.9 6.0 6.8 6.4 6.1 4.0 5.0 4.7 5.0 4.4 3.7 2.0 3.0 1.3 0.0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 6 2022 Q4/YE EARNINGS
Slide 7: INBRIJA Trends Since Launch
INBRIJA Trends Since Launch TRX $M 4000 3500 3793 3464 3546 3000 3361 3319 3249 3300 3110 3070 3125 2992 2995 2500 2817 2761 2000 1915 1500 1000 500 79 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 7 2022 Q4/YE EARNINGS
Slide 8: INBRIJA Trends Since Launch
INBRIJA Trends Since Launch Cartons Dispensed to Patients $M 12000 10000 11029 10135 9924 10102 9528 8000 8883 8737 9087 8514 8305 7857 7839 6000 6909 6955 4000 4198 2000 174 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 8 2022 Q4/YE EARNINGS
Slide 9: Growing the INBRIJA US Trajectory in 2023
Growing the INBRIJA US Trajectory in 2023 2023 US net revenue guidance of $38M - $42M 2023 goal: increase patients trialing Inbrija – Inbrija has 67% market share for on-demand treatments – Only 2% of 380,000 eligible PWP are on an on-demand treatment 9 2022 Q4/YE EARNINGS
Slide 10: New Brand Campaign is Having an Impact
New Brand Campaign is Having an Impact Emphasizing the emotional impact of OFF periods on everyday activities for patients and care partners Educating on the importance of on- demand treatments Increasing investment in digital promotion Q4 vs Q3 22: returning website visitors increased 145% Q4 vs Q3
Slide 11: Ampyra
Ampyra ® 2021 Q4/YEAR END EARNINGS 11
Slide 12: AMPYRA Net U.S. Sales – Q4 and YE 2022
AMPYRA Net U.S. Sales – Q4 and YE 2022 $73M $19M 2022 Q4 2022 net sales net sales 13.7% < 2021 16.6% < 2021 2022 Guidance $68M - $78M 12 2022 Q4/YE EARNINGS
Slide 13: Maintaining Branded AMPYRA
Maintaining Branded AMPYRA Net Sales, $MM 70 64.2 60 50 $44.2 $40.6 $40.8 40 $37.6 30 $25.8 $27.2 $25.3 $21.8 $22.5 $21.1 $19.9 $20.3 $20.0 $18.8 20 $18.2 $14.9 10 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2022 13 2022 Q4/YE EARNINGS
Slide 14: Maintaining Branded AMPYRA
Maintaining Branded AMPYRA Annual net sales expected to stabilize at $60+M / year Field team continues to promote the brand ~200 HCPs resumed prescribing of AMPYRA in 2022 Physician and patient brand loyalty has helped to maintain access ~70% of all covered lives have access to AMPYRA1 1 MMIT Nation
Slide 15: Financials
Financials 15 2022 Q4/YE EARNINGS
Slide 16: 2022 Additional / Ex-U.S. Revenue
2022 Additional / Ex-U.S. Revenue INBRIJA ex-US $ 2.9M FAMPYRA royalty $11.7M Neurelis Inc. royalty $ 2.6M Asieris Pharma license $ 0.5M 16 2022 Q4/YE EARNINGS
Slide 17: 2022 Financial Summary
2022 Financial Summary ∆ YTD YTD ∆ ($ in millions) 4Q’22 4Q’21 Q/Q 2022 2021 YTD/YTD Net Global Inbrija Revenue 9.1 10.4 (12.5%) 30.9 29.6 4.4% Net Ampyra Revenue 18.8 22.5 (16.4%) 72.9 84.6 (13.8%) R&D 1.2 1.4 (14.3%) 5.8 10.4 (44.2%) SG&A 26.3 28.4 (7.4%) 106.3 124.4 (14.6%) GAAP Net Income (Loss)
Slide 18: 2023 Financial Guidance
2023 Financial Guidance INBRIJA U.S. net revenue $38M - $42M AMPYRA U.S. net revenue $65M - $70M Adjusted OpEx $93M - $103M Ending Cash Balance $43M - $47M 18 2022 Q4/YE EARNINGS
Slide 19: 2023 Priorities to Build Shareholder Value
2023 Priorities to Build Shareholder Value Accelerate INBRIJA trajectory -Additional ex-US INBRIJA agreements Maintain AMPYRA Continued fiscal discipline -Cash flow positive 2023 ARCUS collaborations 19 2022 Q4/YE EARNINGS
Slide 20: LIFE. SCIENCE.
LIFE. SCIENCE. °